Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,569,354
App. No.: 13/674,290
Granted: Oct 29, 2013
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

Claims (28)

1. A method of improving cognition in α patient suffering from Schizophrenia or Alzheimer's disease, comprising:

administering to said patient a daily dose of 3 mg, 2.70 mg, 2.50 mg, 2.25 mg, 2 mg, 1.75 mg, 1.50 mg, 1.25 mg, 1 mg, 0.7 mg, 0.5 mg, 0.3 mg, or 0.1 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride; (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate; or (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride solvate.

3. The method of claim 2 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is administered to said patient.

4. The method of claim 3 , wherein the daily dose is 1 mg, 2 mg, or 3 mg.

5. The method of claim 3 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride.

6. The method of claim 3 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate.

7. The method of claim 6 , wherein the daily dose is 1 mg.

8. The method of claim 6 , wherein the daily dose is 2 mg.

9. The method of claim 6 , wherein the daily dose is 3 mg.

10. The method of claim 1 , wherein the patient is suffering from Schizophrenia.

11. The method of claim 10 , wherein the schizophrenia comprises a paranoid type, a disorganized type, catatonic type, or an undifferentiated type.

12. The method of claim 10 , wherein the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition.

13. The method of claim 1 , wherein the patient is suffering from Alzheimer's disease.

14. The method of claim 13 , wherein the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition.

15. A method of improving cognition in a patient suffering from Schizophrenia or Alzheimer's disease, comprising:

administering to said patient a pharmaceutical composition comprising a daily dose of 3 mg, 2.70 mg, 2.50 mg, 2.25 mg, 2 mg, 1.75 mg, 1.50 mg, 1.25 mg, 1 mg, 0.7 mg, 0.5 mg, 0.3 mg, or 0.1 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride; (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate; or (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride solvate.

17. The method of claim 16 , wherein the pharmaceutical composition comprises the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide.

18. The method of claim 17 , wherein the daily dose is 1 mg, 2 mg, or 3 mg.

19. The method of claim 17 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride.

20. The method of claim 17 , wherein the pharmaceutically acceptable salt of the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate.

21. The method of claim 20 , wherein the daily dose is 1 mg.

22. The method of claim 20 , wherein the daily dose is 2 mg.

23. The method of claim 20 , wherein the daily dose is 3 mg.

24. The method of claim 15 , wherein the patient is suffering from Schizophrenia.

25. The method of claim 24 , wherein the schizophrenia comprises a paranoid type, a disorganized type, catatonic type, or an undifferentiated type.

26. The method of claim 15 , wherein the patient is suffering from Alzheimer's disease.

Assignments (3)

SECURITY INTEREST Recorded Jul 5, 2016

From: FORUM PHARMACEUTICALS INC.

To: FMR LLC

Reel/Frame 039254/0828 →

CHANGE OF NAME Recorded Apr 21, 2014